416 related articles for article (PubMed ID: 30706322)
1. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
4. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
5. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
Nagamine T; Fukuda I
No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Cushing's Disease Caused by a TPIT-Lineage Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor: A Case Report.
Wu W; Fu X; Guo W; Chen H
Neuro Endocrinol Lett; 2024 Jan; 45(1):76-80. PubMed ID: 38295430
[TBL] [Abstract][Full Text] [Related]
7. Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report.
de Silva NL; Somasundaram N; Constantine R; Kularatna H
BMC Endocr Disord; 2021 May; 21(1):93. PubMed ID: 33933049
[TBL] [Abstract][Full Text] [Related]
8. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
9. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract][Full Text] [Related]
11. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
12. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
13. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma.
Rotman LE; Vaughan TB; Hackney JR; Riley KO
World Neurosurg; 2019 Feb; 122():417-423. PubMed ID: 30447452
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
16. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
17. Mixed Sparsely Granulated Lactotroph and Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor Expands the Spectrum of Neuroendocrine Neoplasms in Ovarian Teratomas: the Role of Pituitary Neuroendocrine Cell Lineage Biomarkers.
Hodgson A; Pakbaz S; Shenouda C; Francis JA; Mete O
Endocr Pathol; 2020 Sep; 31(3):315-319. PubMed ID: 32632841
[No Abstract] [Full Text] [Related]
18. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
19. Cytopathologic features of pituitary carcinoma with cervical vertebral bone metastasis: a case report.
Ceyhan K; Yagmurlu B; Dogan BE; Erdogan N; Bulut S; Erekul S
Acta Cytol; 2006; 50(2):225-30. PubMed ID: 16610696
[TBL] [Abstract][Full Text] [Related]
20. Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.
Gur C; Lalazar G; Salmon A; Dubiner V; Gross DJ
Pituitary; 2008; 11(3):293-7. PubMed ID: 17638085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]